You need to enable JavaScript to run this app.
FDA clarifies deferral policy on pediatric studies for new cancer drugs
Regulatory News
Joanne S. Eglovitch
Clinical Trials
Compliance
North America
Pharmaceuticals
Preclinical study
Regulatory Intelligence/Policy